Researchers are still evaluating the utility of hydroxychloroquine for treatment or prevention of COVID-19, but it still has well documented use in helping millions of people around the world manage some autoimmune diseases such as lupus and rheumatoid arthritis. West Virginia University researchers Mark McLaughlin and Gabriel Garcia are exploring how tiny changes to the molecular structures of hydroxychloroquine and its predecessor, chloroquine, can improve the drugs’ performance and reduce their side effects . . .

You have reached content available exclusively to Welch News digital subscribers.

Receive a 3-day free trial of unlimited digital access.

Already a subscriber? Login here.